Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SVRA

SVRA - Savara Inc Stock Price, Fair Value and News

4.08USD+0.02 (+0.49%)Market Closed

Market Summary

SVRA
USD4.08+0.02
Market Closed
0.49%

SVRA Stock Price

View Fullscreen

SVRA RSI Chart

SVRA Valuation

Market Cap

563.8M

Price/Earnings (Trailing)

-8.74

Price/Sales (Trailing)

2.7K

EV/EBITDA

-10.65

Price/Free Cashflow

-9.39

SVRA Price/Sales (Trailing)

SVRA Profitability

EBT Margin

-26821.79%

Return on Equity

-52.92%

Return on Assets

-40.74%

Free Cashflow Yield

-10.65%

SVRA Fundamentals

SVRA Revenue

Revenue (TTM)

257.0K

SVRA Earnings

Earnings (TTM)

-64.5M

Earnings Growth (Yr)

-92.73%

Earnings Growth (Qtr)

-26.38%

Breaking Down SVRA Revenue

Last 7 days

3.0%

Last 30 days

-15.5%

Last 90 days

-13.4%

Trailing 12 Months

28.3%

How does SVRA drawdown profile look like?

SVRA Financial Health

Current Ratio

14.9

Debt/Equity

0.22

Debt/Cashflow

-2.26

SVRA Investor Care

Shares Dilution (1Y)

21.15%

Diluted EPS (TTM)

-0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202022.3M14.9M7.6M257.0K
201900029.6M
201815.0M22.3M00
20177.7M000
2016140.5K227.0K313.5K400.0K
201500054.0K
2010000489.0K

Tracking the Latest Insider Buys and Sells of Savara Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 21, 2024
erickson anne
sold (taxes)
-1,832
4.81
-381
chief business officer
Dec 28, 2023
pauls matthew
gifted
-
-
-19,000
chief executive officer
Dec 28, 2023
pauls matthew
sold
-395,900
4.7131
-84,000
chief executive officer
Dec 28, 2023
lowrance david l
sold
-47,131
4.7131
-10,000
chief financial officer
Dec 28, 2023
elam nevan c
sold
-442,291
4.7131
-93,843
-
Dec 28, 2023
elam nevan c
acquired
69,721
1.29695
53,758
-
Dec 15, 2023
lowrance david l
gifted
-
-
-20,000
chief financial officer
Dec 14, 2023
ramsay david a
acquired
-
-
22,500
-
Dec 14, 2023
hawkins richard j
acquired
-
-
22,500
-
Dec 14, 2023
elam nevan c
acquired
-
-
22,500
-

1–10 of 50

Which funds bought or sold SVRA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 29, 2024
Opaleye Management Inc.
new
-
4,257,900
4,257,900
0.93%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
reduced
-61.72
-17,476,800
11,923,600
0.05%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.32
55,654
129,654
0.02%
May 16, 2024
COMERICA BANK
new
-
1,120
1,120
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
411
308,526
378,410
-%
May 16, 2024
JANE STREET GROUP, LLC
added
42.00
143,376
427,528
-%
May 16, 2024
AWM Investment Company, Inc.
new
-
498,000
498,000
0.06%
May 15, 2024
Sofinnova Investments, Inc.
reduced
-1.49
490,035
11,689,400
0.65%
May 15, 2024
DEUTSCHE BANK AG\
added
2,173
3,598,470
3,754,350
-%
May 15, 2024
STATE STREET CORP
added
6.34
1,052,870
9,362,720
-%

1–10 of 49

Are Funds Buying or Selling SVRA?

Are funds buying SVRA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SVRA
No. of Funds

Unveiling Savara Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 12, 2024
bain capital life sciences fund ii, l.p.
9.99%
14,565,457
SC 13D/A
Feb 14, 2024
zambon spa
3.46%
4,680,000
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners ii, l.p.
2.6%
3,500,000
SC 13G/A
Feb 13, 2024
caxton corp
0.3%
353,441
SC 13G/A
Feb 13, 2024
prudential financial inc
7.23%
0
SC 13G
Feb 08, 2024
jennison associates llc
6.5%
8,815,358
SC 13G
Feb 07, 2024
adage capital partners gp, l.l.c.
5.64%
7,637,930
SC 13G/A
Feb 01, 2024
farallon capital partners, l.p.
1.9%
2,542,599
SC 13G/A
Jan 31, 2024
blackrock inc.
5.4%
7,261,530
SC 13G
Jul 26, 2023
growth equity opportunities 17, llc
18.1%
24,471,264
SC 13D/A

Recent SEC filings of Savara Inc

View All Filings
Date Filed Form Type Document
Jun 10, 2024
8-K/A
Current Report
Jun 07, 2024
8-K
Current Report
May 21, 2024
EFFECT
EFFECT
May 09, 2024
S-3
S-3
May 09, 2024
10-Q
Quarterly Report
Apr 26, 2024
DEFA14A
DEFA14A
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
ARS
ARS
Apr 23, 2024
4
Insider Trading
Apr 12, 2024
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to Savara Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Savara Inc News

Latest updates
MarketBeat6 hours ago
Seeking Alpha07 Jun 202409:56 am

Savara Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2020Q42020Q32020Q22020Q12019Q42018Q22018Q12017Q12016Q42016Q32016Q22016Q12015Q42010Q4
Revenue--------0.000.000.00----
Operating Expenses17.9%13.0011.009.0016.0032.0012.00--------
  S&GA Expenses-48.1%3.005.003.003.003.002.00--------
Interest Expenses-----1.000.000.00-------
Income Taxes-------0.28-4.55-0.24------
Earnings Before Taxes----9.39-15.42-31.72-11.59-31.40-5.21-1.95-3.23-2.05---
Net Income-24.2%-13.74-11.06-9.39-15.42-31.72-11.59--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-10.9%15817818212012914014815716617718719620898.00109115120136141147148
  Current Assets-11.9%14616617010811812913714515516517518319585.0096.00103107124108114108
    Cash Equivalents-36.9%17.0027.0028.0023.0034.0052.0012095.0079.0034.0045.0041.0056.0023.0035.0047.0035.0050.0018.0017.0026.00
  Net PPE-8.1%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
  Goodwill-------------------19.0019.0027.00
Liabilities-2.0%36.0037.0036.0032.0031.0032.0031.0030.0030.0032.0032.0031.0033.0033.0033.0031.0033.0035.0034.0035.0046.00
  Current Liabilities-7.4%10.0011.009.006.005.006.005.004.0016.0015.0011.006.007.008.008.006.008.0011.008.009.009.00
  Long Term Debt0.3%26.0026.0026.0026.0026.0026.0026.0026.0013.0017.0021.0025.0025.0025.00-------
    LT Debt, Current---------13.008.004.00----------
    LT Debt, Non Current0.3%26.0026.0026.0026.0026.0026.0026.0026.0013.0017.0021.0025.0025.0025.00-------
Shareholder's Equity-13.2%12214014788.0098.0010811712713614415516517564.0077.0084.0087.00102107113102
  Retained Earnings-5.2%-413-393-377-360-349-338-328-317-308-300-289-278-267-257-243-232-223-207-176-163-141
  Additional Paid-In Capital0.4%536534525449448447446446445445444443442321320316311310283276244
Shares Outstanding0.0%13813813511415311415315315311415315277.00--------
Float----410---159---180---116---78.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-32.3%-20,644-15,600-13,200-10,274-12,026-8,651-8,162-9,316-8,425-9,363-8,927-12,194-9,597-12,300-6,705-7,752-13,079-9,946-11,413-12,905-10,859
  Share Based Compensation65.8%2,2571,3619959588645614504565748536907719464391,9311,1751,9311,1491,1461,1471,000
Cashflow From Investing64.3%10,7936,571-56,586-1,006-6,095-59,21132,99625,19553,665-1,26812,983-3,432-77,739-381-6,86118,080-1,78516,7516,590-14,9217,320
Cashflow From Financing-99.4%49.007,89574,75510426.001.00-1.0088.00-1.006.0010.00324120,466-1,8272,328-46625,2485,70819,0564,896
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SVRA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 16,807$ 8,738
General and administrative5,6363,366
Depreciation and amortization328
Total operating expenses22,47512,112
Loss from operations(22,475)(12,112)
Other income (expense)  
Interest income1,353765
Foreign currency exchange gain (loss)(21)29
Tax credit income797761
Total other income, net2,1291,555
Net loss$ (20,346)$ (10,557)
Net loss per share:  
Basic$ (0.11)$ (0.07)
Diluted$ (0.11)$ (0.07)
Weighted-average common shares outstanding:  
Basic182,550,109152,781,580
Diluted182,550,109152,781,580
Other comprehensive income (loss):  
Gain (loss) on foreign currency translation$ (220)$ 130
Unrealized gain (loss) on short-term investments(251)14
Total comprehensive loss$ (20,817)$ (10,413)

SVRA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 16,785$ 26,585
Short-term investments126,258135,734
Prepaid expenses and other current assets3,1443,628
Total current assets146,187165,947
Property and equipment, net248270
In-process R&D10,71210,960
Other non-current assets1,148387
Total assets158,295177,564
Current liabilities:  
Accounts payable2,8533,504
Accrued expenses and other current liabilities6,9577,093
Total current liabilities9,81010,597
Long-term liabilities:  
Long-term debt26,41626,348
Other long-term liabilities208247
Total liabilities36,43437,192
Commitments and Contingencies (Note 9)
Stockholders’ equity:  
Common stock, $0.001 par value, 300,000,000 authorized as of March 31, 2024 and December 31, 2023; 138,176,641 and 138,143,545 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively140140
Additional paid-in capital536,178533,872
Accumulated other comprehensive loss(742)(271)
Accumulated deficit(413,715)(393,369)
Total stockholders’ equity121,861140,372
Total liabilities and stockholders’ equity$ 158,295$ 177,564
SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.
 CEO
 WEBSITEsavarapharma.com
 INDUSTRYBiotechnology
 EMPLOYEES28

Savara Inc Frequently Asked Questions


What is the ticker symbol for Savara Inc? What does SVRA stand for in stocks?

SVRA is the stock ticker symbol of Savara Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Savara Inc (SVRA)?

As of Fri Jun 14 2024, market cap of Savara Inc is 563.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SVRA stock?

You can check SVRA's fair value in chart for subscribers.

What is the fair value of SVRA stock?

You can check SVRA's fair value in chart for subscribers. The fair value of Savara Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Savara Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SVRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Savara Inc a good stock to buy?

The fair value guage provides a quick view whether SVRA is over valued or under valued. Whether Savara Inc is cheap or expensive depends on the assumptions which impact Savara Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SVRA.

What is Savara Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, SVRA's PE ratio (Price to Earnings) is -8.74 and Price to Sales (PS) ratio is 2.73 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SVRA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Savara Inc's stock?

In the past 10 years, Savara Inc has provided 0.203 (multiply by 100 for percentage) rate of return.